Lysoway Therapeutics Announces Preclinical Data Supporting First-in-Class TRPML1 Agonist LW-1017 in Scientific Reports
Lysoway Therapeutics, a clinical-stage biotechnology company pioneering therapeutics targeting lysosomal ion channels for age-related neurodegenerative diseases, today announced the publication of preclinical data evaluating its lead candidate, LW-1017, in Scientific Reports, a journal from Nature Portfolio.
